10X Capital Venture Acquisition Corp. III - VCXBU STOCK NEWS

Welcome to our dedicated page for 10X Capital Venture Acquisition III news (Ticker: VCXBU), a resource for investors and traders seeking the latest updates and insights on 10X Capital Venture Acquisition III stock.

10X Capital Venture Acquisition Corp. III (NYSE American: VCXB.U, VCXB, VCXB WS) is a special purpose acquisition company sponsored by 10X Capital, focused on identifying high growth businesses domestically and abroad and bringing them to the public markets. Recently, the company received a notice from the New York Stock Exchange Regulation, Inc. for not timely filing its Annual Report on Form 10-K for the fiscal year ended December 31, 2023. Despite this, 10X III intends to cure its non-compliance and continue its mission of finding and taking businesses public.

04/23/2024 04:42 PM

News

10X Capital Venture Acquisition Corp. III Receives NYSE Notice Regarding Late Form 10-K Filing

Rhea-AI Summary

10X Capital Venture Acquisition Corp. III (VCXB) received a notice from NYSE American regarding the late filing of its Annual Report on Form 10-K for the fiscal year ended December 31, 2023. The company's independent registered public accounting firm needed more time to review its financial statements. 10X III has a six-month Cure Period to file the report and regain compliance with NYSE American's listing standards.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Addimmune, a Clinical Stage Hiv-Focused Gene Therapy Company, to go Public Through Business Combination With 10x Capital Venture Acquisition Corp. III

Rhea-AI Summary

American Gene Technologies International Inc. (AGT) and 10X Capital Venture Acquisition Corp. III (VCXB) announced a merger agreement to form Addimmune, a publicly listed company focused on developing a functional cure for HIV. The investigational cell therapy, AGT103-T, has shown positive safety results in Phase I trials and will be targeted towards the 38 million people living with HIV globally. The proposed transaction represents a pre-money enterprise value of $500 million for Addimmune, with an additional earnout of up to $300 million tied to clinical and priced-based milestones.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

1.43%

FAQ

What is 10X Capital Venture Acquisition Corp. III?

10X Capital Venture Acquisition Corp. III is a special purpose acquisition company sponsored by 10X Capital, focused on identifying high growth businesses.

What is the recent notice received by 10X III?

10X III received a notice from the New York Stock Exchange Regulation, Inc. for not timely filing its Annual Report on Form 10-K for the fiscal year ended December 31, 2023.

How does 10X III plan to address the non-compliance issue?

10X III intends to cure its non-compliance with the NYSE American's continued listing standards by filing the Annual Report within the Cure Period.

What is the focus of 10X Capital?

10X Capital is focused on identifying high growth businesses domestically and abroad and bringing them to the public markets.

What are the key objectives of 10X Capital Venture Acquisition Corp. III?

The key objectives include finding and taking high growth businesses public.

How can investors contact 10X Capital?

For investors, please contact ir@10xcapital.com.

Who can media contact for Addimmune?

For media inquiries related to Addimmune, please contact Kathy Fowler at kfowler@addimmune.com or phone: (410) 963-2345.

Where is 10X Capital Venture Acquisition Corp. III based?

10X Capital Venture Acquisition Corp. III is based in New York, NY.

What are the ticker symbols of 10X Capital Venture Acquisition Corp. III?

The ticker symbols are VCXB.U, VCXB, and VCXB WS.

Where can I find more information about 10X Capital Venture Acquisition Corp. III?

For more information, visit https://www.10xspac.com/spaciii.

10X Capital Venture Acquisition Corp. III

NYSE:VCXBU

VCXBU Rankings

N/A Ranked by Market Cap

N/A Ranked by Dividends